Serum to conduct clinical studies on proteins developed with Lipoxen's technology

17-Jan-2005
Serum Institute of India will be conducting clinical studies on eight protein drugs including EPO, GCSF, Doxorubicin, flu and pneumococcal vaccines. These drugs have been developed using the patented polymer conjugation technology PolyXen and ImuXen provided by Lipoxen Technologies Ltd. In PolyXen, the protein is conjugated with polysalic acid, increasing the molecular mass of the molecule. For ImuXen, used for DNA vaccines, the DNA of the virus (which produces the antigen) and the antigen itself are entrapped within Lyposomes. Both technologies enhance the life of the protein or a vaccine and protect it from degradation in blood.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances